QUIA PHARMA AB (FRA:99B0) Other Long-Term Liabilities: €-0.00 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is QUIA PHARMA AB Other Long-Term Liabilities?

QUIA PHARMA AB FRA:99B0 Other Long-Term Liabilities is €-0.00 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

QUIA PHARMA AB's other long-term liabilities for the quarter that ended in Jun. 2025 was €-0.00 Mil.

QUIA PHARMA AB's quarterly other long-term liabilities declined from Jun. 2024 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) and declined from Dec. 2024 (€0.00 Mil) to Jun. 2025 (€-0.00 Mil).

QUIA PHARMA AB's annual other long-term liabilities increased from Dec. 2022 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil) and increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil).

QUIA PHARMA AB Other Long-Term Liabilities Related Terms

QUIA PHARMA AB Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for QUIA PHARMA AB's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

QUIA PHARMA AB Other Long-Term Liabilities Chart

QUIA PHARMA AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.00 0.00

QUIA PHARMA AB Semi-Annual Data
Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Jun17 Jun20 Dec21 Jun23 Dec23 Jun24 Dec24 Jun25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00

QUIA PHARMA AB Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €-0.00 Mil mean?
QUIA PHARMA AB (FRA:99B0) has a Other Long-Term Liabilities of €-0.00 Mil as of Jun. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on QUIA PHARMA AB and its competitors.
Is QUIA PHARMA AB's Other Long-Term Liabilities too high?
QUIA PHARMA AB's current Other Long-Term Liabilities is €-0.00 Mil.
How does QUIA PHARMA AB's Other Long-Term Liabilities compare to VRTX and REGN?
QUIA PHARMA AB's Other Long-Term Liabilities of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on QUIA PHARMA AB and its competitors. QUIA PHARMA AB's current Other Long-Term Liabilities is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QUIA PHARMA AB stock overvalued right now?
QUIA PHARMA AB (FRA:99B0) has a current Other Long-Term Liabilities of €-0.00 Mil. The current Other Long-Term Liabilities is €-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For QUIA PHARMA AB (FRA:99B0), the current Other Long-Term Liabilities is €-0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

QUIA PHARMA AB Business Description

Address Virdings Alle 32 B, Uppsala, SWE, 754 50
QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon.